TuHURA Biosciences, Inc. (HURA) borrowed an additional $650,000 on September 21, 2026, under its revolving credit facility with Parkview Holdings One LLC. The facility provides maximum loan availability of $50 million and matures on April 21, 2031; TuHURA expects to use the draw for general corporate purposes.
TuHURA said future draws depend on satisfying the facility’s conditions and that funds available may be insufficient for operations and development programs as anticipated. It also identified potential conflicts of interest arising from the lender’s affiliation with its largest stockholder.
TuHURA Biosciences, Inc. (HURA) reports a new borrowing under its existing revolving credit facility with Parkview Holdings One LLC. The facility provides up to $50 million in loan availability and matures on April 21, 2031. On September 14, 2026, TuHURA drew an additional $650,000 and plans to use the proceeds for general corporate purposes, increasing its outstanding debt under this line. The company highlights that its ability to continue drawing on the facility depends on satisfying loan conditions and maintaining compliance, and notes risk that available funds could be insufficient for its operations and development programs, as well as potential conflicts of interest because the lender is affiliated with its largest stockholder.
TuHURA Biosciences, Inc. (HURA) filed an amendment to clarify details of its newly adopted 2026 Inducement Equity Incentive Plan, which the Board approved on September 10, 2026 under Nasdaq Listing Rule 5635(c)(4). The plan reserves 5,000,000 shares of common stock for equity awards to new employees as a material inducement to employment. Awards may include nonqualified stock options and other stock-based awards, but no incentive stock options. As of adoption, no equity awards have been granted, and the Board currently expects all awards to be stock options with an exercise price at or above the closing price on the grant date. Shares reserved under the plan will only become issued and outstanding if the options granted to new employees vest and are exercised.
TuHURA Biosciences, Inc. (HURA) adopted the TuHURA Biosciences, Inc. 2026 Inducement Equity Incentive Plan on September 10, 2026, allowing equity awards to new employees as a material inducement to employment under Nasdaq Listing Rule 5635(c)(4). The Board reserved 5,000,000 shares of common stock for issuance under this plan.
The plan, administered by the Board’s Compensation Committee or a majority of independent directors, permits nonqualified stock options, stock appreciation rights, stock, restricted stock, restricted stock units, performance shares, performance units and other stock-based awards, but does not permit incentive stock options. TuHURA also approved a related form of stock option agreement to be used with this inducement plan.
TuHURA Biosciences, Inc. (HURA) reports a new borrowing under its existing revolving credit facility with Parkview Holdings One LLC. The facility, previously disclosed, has a maximum availability of $50 million and matures on April 21, 2031. On September 2, 2026, the company drew an additional $1,500,000 and states it expects to use the funds for general corporate purposes.
The company highlights forward-looking risks related to its ability to continue drawing funds under the Loan Agreement, the possibility that available funds may not be sufficient for its operations and development programs, and notes potential conflicts of interest because the lender is an affiliate of its largest stockholder.
TuHURA Biosciences, Inc. (HURA) discloses that its President, Chief Executive Officer and director, James A. Bianco, M.D., now beneficially owns 3,085,519 shares of common stock, or 4.6% of the company’s outstanding common stock. This total includes 2,173,307 shares and 912,212 shares issuable upon option exercises within 60 days.
Dr. Bianco’s ownership percentage fell below 5% solely because TuHURA issued 1,878,287 additional shares of common stock to Parkview Holdings One LLC under an April 21, 2026 Fee Letter, increasing total shares outstanding to 65,758,360 as of August 18, 2026. He reports no purchases or sales of TuHURA stock in connection with this change and continues in his executive and director roles. This amendment serves as an exit filing for his more-than-5% beneficial owner status.
TuHURA Biosciences, Inc. (HURA) reports an additional borrowing under its existing revolving credit facility with Parkview Holdings One LLC. The facility provides up to $50 million of loan availability and matures on April 21, 2031.
On August 20, 2026, the company drew an additional $650,000 and expects to use these funds for general corporate purposes. The lender is an affiliate of the company’s largest stockholder, and TuHURA highlights risks related to conditions for future drawdowns, sufficiency of available funds, and potential conflicts of interest.
TuHURA Biosciences, Inc. (HURA) reported results of its 2026 Annual Meeting and the approval of equity issued in connection with an existing credit facility. Stockholders approved issuing 1,878,287 common shares to Parkview Holdings One LLC as “Loan Fee Shares” under a previously agreed $50 million revolving credit facility, relying on private placement exemptions for an accredited investor.
Six directors were elected to serve until the 2027 annual meeting. An advisory vote approved named executive officer compensation, and stockholders indicated a preference for conducting future say-on-pay votes every three years. Cherry Bekaert LLP was ratified as independent auditor for the year ending December 31, 2026. A quorum was present, with 43,034,024 of 63,682,528 outstanding shares represented.
TuHURA Biosciences, Inc. is a clinical-stage immuno-oncology company developing three main technologies, led by IFx-2.0, an innate immune agonist in a Phase 3 registration trial for Merkel cell carcinoma using the FDA’s accelerated approval pathway. The company is also preparing a Phase 1b/2 trial for TBS-2025, a VISTA-inhibiting antibody for mutNPM1 acute myeloid leukemia, and advancing Delta Opioid Receptor–targeted ADCs.
For the six months ended June 30, 2026, TuHURA reported a net loss of $16.8 million and no product revenue, driven mainly by $11.9 million in research and development and $4.4 million in general and administrative expenses. Cash used in operating activities was $13.0 million. As of June 30, 2026, the company had $1.0 million in cash and cash equivalents, total assets of $31.7 million, and an accumulated deficit of $157.9 million.
Liquidity is supported by a new $50 million revolving credit facility with Parkview, of which $3.6 million had been drawn by June 30 and approximately $5.8 million by mid-August 2026, plus an at-the-market equity program and prior equity offerings. Management expects existing capital resources, together with anticipated credit facility drawdowns, to fund planned operations into the end of 2028.
TuHURA Biosciences, Inc., a Phase 3 immuno-oncology company, reported second quarter 2026 results and a corporate update focused on advancing IFx-2.0, TBS-2025 and MDSC inhibitor ADC programs. The company highlighted multiple expected milestones through 2027, including prospective orphan drug designations and key trial initiations and readouts.
TuHURA reported cash and cash equivalents of $1.0 million as of June 30, 2026, and noted access to a recently announced $50 million term credit facility from its largest shareholder, described as non-convertible and expected to extend its cash runway into 2028. The facility bears 12% annual interest, with interest paid monthly and principal due at maturity on April 21, 2031, and can be drawn as needed to fund clinical and operating expenses.
For the quarter, research and development expenses were $6.6 million versus $4.9 million a year earlier, mainly from increased clinical activity, while general and administrative expenses were $2.1 million versus $1.9 million, driven in part by non-cash stock compensation and public company costs. Net cash outflows from operating activities were $13.0 million for the six months ended June 30, 2026, compared with $10.9 million in the prior-year period, partially offset by $10.6 million of net cash from financing activities. Common shares outstanding were approximately 63.7 million at June 30, 2026.